JPRN-UMIN000015123已完成2 期
Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neck - S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neck
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)History of severe hypersensitivity (2)Active infection (3)Severe and uncontrolled complication(severe heart failure, cerebrovascular disease, pulmonary fibrosis, renal failure, liver failure, active peptic ulcer, uncontrolled diabetes mellitus, uncontrolled hypertention, etc.) (4)Uncontrolled pleural, pericardial effusion or ascites (5)Symptomatic brain metastasis (6)Simultaneous or metachronous double cancers within the past 5 years other than skin cancer (malignant melanoma is excluded), carcinoma in situ of uterine cervix and mucosal carcinoma of digestive tract (7)Receiving flucytocine (8)HBs Ag positive (9)Pregnant or lactating women or women of childbearing potential and men in hope of the pregnancy of the partner (10)Unstable psychiatric disease (11)Surgery or radiotherapy within 4 weeks (12)Decision of ineligibility by a physician
研究者
相似试验
已完成
2 期
Phase II trial of S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavityAdvanced recurrent/metastatic carcinoma of the oral cavityJPRN-UMIN000024371Osaka University20
招募中
不适用
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancercolorectal cancerJPRN-UMIN000003703Toho University school of Medicine10
招募中
1 期
Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal CancerJPRN-UMIN000004124Kinki university school of medicine Department of clinical oncology21
招募中
1 期
Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.Colorectal cancer: KRAS wild typeJPRN-UMIN000003288Kyushu Medical Oncology Group40
尚未招募
1 期
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000012074Kyorin University School of Medicine, Department of Otolaryngology30